New Wake Forest study to pin down soy's active ingredient

August 20, 1999

WINSTON-SALEM -- Scientists at Wake Forest University School of Medicine are beginning a five-year study to determine which ingredients in soybeans are the active ones in protecting against heart disease, stroke, cancer and osteoporosis.

Under a new $2.4 million grant from the National Heart, Lung and Blood Institute, the research team, headed by Thomas B. Clarkson, D.V.M., will focus on two isoflavones (also called phytoestrogens -- plant estrogens) in soy: genistein and daidzein.

Clarkson, professor of pathology (comparative medicine), said he is seeking to identify the optimum doses and ratios of genistein to daidzein.

He said, "We have obtained preliminary evidence suggesting that predominantly daidzein rather than predominantly genistein may be of greater cardiovascular benefit."

Genistein is the predominant phytoestrogen in the outer portion of soybeans. Daidzein predominates in the germ of the soybean, he said. (Soy resembles wheat in that respect -- most people want whole wheat, but wheat germ also is available, and some prefer that.) The outer portion is 3 to 1 genistein; the germ is 4 to 1 daidzein.

Most studies so far have focused on genistein as the active ingredient in preventing cardiovascular diseases and cancer.

The comparison between different ratios of daidzein and genistein is just one phase of the project which will "explore several unanswered questions concerning the optimal use of soy supplements by both males and females."

Clarkson said he hopes to pin down just how much soy is needed for the optimum preventive dose of phytoestrogen and the optimum therapeutic dose. (The preventive dose is usually much smaller than the therapeutic dose, in which the active ingredients of the food essentially act as a drug.)

And the research team is looking at safety issues as well: how safe is soy for the breasts and uteri of females and what effect, if any, does phytoestrogen have on the reproductive systems of males.

The studies will be conducted in monkeys. Previous work in the monkey colony at Wake Forest has developed evidence that soy phytoestrogens may be a useful alternative to traditional hormone replacement therapy in postmenopausal females, protecting against coronary heart disease and other diseases that ordinarily increase dramatically after menopause.

"Our concentration on postmenopausal females and soy phytoestrogens has increased our awareness of the public health importance of the simultaneous protective effects of soy phytoestrogens on coronary heart disease and hormone dependent cancers," Clarkson said.

The group also has preliminary evidence from a study in young male monkeys that soy may protect against coronary heart disease in males. These studies also indicate that the plant estrogens do not adversely affect the reproductive systems of males.

Clarkson said the developing evidence that soy offers protection against hormone- dependent cancers in females indicates soy "may provide protection against prostate cancer," which is also thought to be affected by hormones. So the new study also will focus on adult male monkeys.

A parallel national pilot study in people, headquartered at Wake Forest, also is testing whether soy will reduce the risk of prostate cancer. "In Asian countries like Japan, where soy consumption is high, prostate cancer rates are lower than in Western countries with low soy intake," said Electra D. Paskett, Ph.D., associate professor of public health sciences (epidemiology) and principal investigator. The pilot study of 160 men would evaluate the effect of soy on markers for prostate cancer risk.

Clarkson noted that studies have shown that despite the far lower prostate cancer rates in Japan, "immigrant studies support the hypothesis that environmental factors (the American diet) are critical in prostate cancer development. Japanese who emigrate to the United States quickly assume the cancer incidence rate of U.S.-born men."
-end-


Wake Forest Baptist Medical Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.